High Fluence Increases the Antibacterial Efficacy of PACK Cross-Linking.
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
pubmed:
19
4
2020
medline:
26
5
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
Photoactivated chromophore for keratitis cross-linking (PACK-CXL) is used as an adjunct therapy to antibiotic medication in infectious keratitis. This experimental study aimed at quantifying the PACK-CXL efficacy as a function of UV fluence using several bacterial strains and irradiated volumes. Six distinct bacterial strains, including standardized strains and clinically isolated strains from patients with keratitis, were analyzed. Bacterial concentrations between 10 and 10 cells/mL were used (simulating small corneal ulcers). Volumes of either 11 μL (≈285 μm stromal thickness) or 40 μL (≈1000 μm stromal thickness) were irradiated within a microtiter plate at different fluences (5.4-27 J/cm) and irradiances (3, 9 and 18 mW/cm). The ratio of bacterial killing (B†) was determined to evaluate the antimicrobial efficacy of PACK-CXL. B† was similar (51 ± 11%) in bacterial concentrations between 10 and 10 per ml. In 11 μL volume, Staphylococcus aureus (SA) 8325-4 ATCC 29213, Bacillus subtilis (BS) 212901, and Pseudomonas aeruginosa (PA) 2016-866624 were most sensitive to PACK-CXL at 5.4 J/cm (on average B† = 49 ± 8%), whereas Klebsiella oxytoca (KO) 2016-86624 (B† = 25%) was least sensitive. When irradiating a larger volume, B† was on average lower in 40 μL (19 ± 18%), compared with 11 μL (45 ± 17%, P < 0.001). By contrast, applying a higher UV fluence increased B† of SA ATCC 29213, from 50% at 5.4 J/cm to 92% at 10.8 J/cm, to 100% at 16.2 J/cm and above. Applying higher UV fluences substantially increases the bacterial killing rates. Safety limits for clinical application require further investigation.
Identifiants
pubmed: 32304431
doi: 10.1097/ICO.0000000000002335
pii: 00003226-202008000-00016
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cross-Linking Reagents
0
Collagen
9007-34-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1020-1026Références
Bharathi MJ, Ramakrishnan R, Meenakshi R, et al. Microbial keratitis in South India: influence of risk factors, climate, and geographical variation. Ophthalmic Epidemiol. 2007;14:61–69.
Knyazer B, Krakauer Y, Baumfeld Y, et al. Accelerated corneal cross-linking with photoactivated chromophore for moderate therapy-resistant infectious keratitis. Cornea. 2018;37:528–531.
Gray TB, Cursons R, Sherwan JF, et al. Acanthamoeba, bacterial, and fungal contamination of contact lens storage cases. Br J Ophthalmol. 1995;79:601–605.
Chan CC, Holland EJ. Infectious keratitis after Boston type 1 keratoprosthesis implantation. Cornea. 2012;31:1128–1134.
Generali E, Cantarini L, Selmi C. Ocular involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol. 2015;49:263–270.
Fernandes M, Sharma S. Polymicrobial and microsporidial keratitis in a patient using Boston scleral contact lens for Sjogren's syndrome and ocular cicatricial pemphigoid. Cont Lens and Anterior Eye. 2013;36:95–97.
Chew SJ, Beuerman RW, Assouline M, et al. Early diagnosis of infectious keratitis with in vivo real time confocal microscopy. CLAO J. 1992;18:197–201.
Mamalis N. The increasing problem of antibiotic resistance. J Cataract & Refractive Surg. 2007;33:1831–1832.
World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. Geneva, Switzerland: World Health Organization; 2014.
Hafezi F, Randleman JB. PACK-CXL: defining CXL for infectious keratitis. J Refract Surg. 2014;30:438–439.
Iseli HP, Thiel MA, Hafezi F, et al. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008;27:590–594.
Makdoumi K, Bäckman A. Photodynamic UVA-riboflavin bacterial elimination in antibiotic-resistant bacteria. Clin Exp Ophthalmol. 2016;44:582–586.
Price MO, Price FW. Corneal cross-linking in the treatment of corneal ulcers. Curr Opin Ophthalmol. 2016;27:250–255.
Arboleda A, Miller D, Cabot F, et al. Assessment of rose bengal versus riboflavin photodynamic therapy for inhibition of fungal keratitis isolates. Am J Ophthalmol. 2014;158:64–70; e62.
Alio JL, Abbouda A, Valle DD, et al. Corneal cross linking and infectious keratitis: a systematic review with a meta-analysis of reported cases. J Ophthalmic Inflamm Infect. 2013;3:47.
Bilgihan K, Kalkanci A, Ozdemir HB, et al. Evaluation of antifungal efficacy of 0.1% and 0.25% riboflavin with UVA: a comparative in vitro study. Curr Eye Res. 2016;41:1050–1056.
Garg P, Das S, Roy A. Collagen cross-linking for microbial keratitis. Middle East Afr J Ophthalmol. 2017;24:18.
Bäckman A, Makdoumi K, Mortensen J, et al. The efficiency of cross-linking methods in eradication of bacteria is influenced by the riboflavin concentration and the irradiation time of ultraviolet light. Acta Ophthalmol (Copenh). 2014;92:656–661.
Richoz O, Kling S, Hoogewoud F, et al. Antibacterial efficacy of accelerated photoactivated chromophore for keratitis–corneal collagen cross-linking (PACK-CXL). J Refract Surg. 2014;30:850–854.
Tal K, Gal-Or O, Pillar S, et al. Efficacy of primary collagen cross-linking with photoactivated chromophore (PACK-CXL) for the treatment of Staphylococcus aureus–induced corneal ulcers. Cornea. 2015;34:1281–1286.
Cosar CB, Kucuk M, Celik E, et al. Microbiologic, pharmacokinetic, and clinical effects of corneal collagen cross-linking on experimentally induced pseudomonas keratitis in rabbits. Cornea. 2015;34:1276–1280.
Makdoumi K, Mortensen J, Sorkhabi O, et al. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2012;250:95–102.
Tabibian D, Richoz O, Riat A, et al. Accelerated photoactivated chromophore for keratitis–corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis. J Refract Surg. 2014;30:855–857.
Ferrari TM, Leozappa M, Lorusso M, et al. Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross-linking: a case report. Eur J Ophthalmol. 2009;19:295.
Said DG, Elalfy MS, Gatzioufas Z, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 2014;121:1377–1382.
Seiler TG, Fischinger I, Koller T, et al. Customized corneal cross-linking: one-year results. Am J Ophthalmol. 2016;166:14–21.
Mazzotta C, Traversi C, Paradiso AL, et al. Pulsed light accelerated crosslinking versus continuous light accelerated crosslinking: one-year results. J Ophthalmol. 2014;2014:604731.
Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209–212.
Altman D, Machin D, Bryant T, et al. Statistics with Confidence: Confidence Intervals and Statistical Guidelines. Bristol: British Medical Journal; 2000.
Kymionis GD, Kouroupaki AI, Liakopoulos DA, et al. Multiorganism, drug-resistant keratitis treated by corneal crosslinking. Eur J Ophthalmol. 2016;26:e67–e70.
Zarei-Ghanavati S, Irandoost F. Treatment of refractory keratitis after a boston type I keratoprosthesis with corneal collagen cross-linking. Cornea. 2015;34:1161–1163.
Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007;26:385–389.
Kanellopoulos AJ, Dupps WJ, Seven I, et al. Toric topographically customized transepithelial, pulsed, very high-fluence, higher energy and higher riboflavin concentration collagen cross-linking in keratoconus. Case Rep Ophthalmol. 2014;5:172–180.
Seiler TG, Batista A, Frueh BE, et al. Riboflavin concentrations at the endothelium during corneal cross-linking in humans. Invest Ophth Vis Sci. 2019;60:2140–2145.
Chan TC, Chow VW, Jhanji V. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for bacterial keratitis after small incision lenticule extraction (SMILE). J Refract Surg. 2017;33:278–280.
Tabibian D, Mazzotta C, Hafezi F, et al. Corneal cross-linking in infectious keratitis. Eye Vis (Lond). 2016;3:11.
Price MO, Tenkman LR, Schrier A, et al. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012;28:706–713.